Celgene Corporation (NASDAQ:CELG) – Celgene Reports Results from the Phase III POSTURE Study Evaluating Oral OTEZLA® in Ankylosing Spondylitis

[Business Wire] – Celgene Corporation today announced results of its phase III POSTURE study evaluating OTEZLA, the company’s oral, selective inhibitor of phosphodiesterase 4 , in patients with active ankylosing spondylitis. Read more . . . → Read More: Celgene Corporation (NASDAQ:CELG) – Celgene Reports Results from the Phase III POSTURE Study Evaluating Oral OTEZLA® in Ankylosing Spondylitis Similar Articles: Company Update: Celgene Corporation (NASDAQ:CELG) – Celgene Corporation to Present at Investor Conferences in June Stock Update (NASDAQ:CELG): Celgene Corporation to Present at Investor Conferences in May Market Update (NASDAQ:CELG): Celgene Corporation to Announce First Quarter 2014 Results on April 24, 2014